EQT Corporation Surges to 234th in Trading Volume with $396 Million Turnover Despite Stock Price Decline

On June 9, 2025, EQT Corporation (EQT) experienced a significant increase in trading volume, with a turnover of $396 million, marking an 83.88% rise from the previous day. This surge placed EQT at the 234th position in terms of trading volume for the day. However, despite the high trading volume, EQT's stock price declined by 2.64%.

EQT Corporation, a leading independent natural gas producer, has been actively involved in various strategic initiatives. One notable development is the transformation of a site into a 3,200-acre natural gas-powered data center campus, which will include a 4.5 gigawatt Marcellus-fired power plant. This project underscores EQT's commitment to leveraging its extensive Appalachian Basin assets to drive growth and innovation in the energy sector.

In terms of valuation, EQT Corporation's intrinsic value has been estimated to range from $17.28 to $68.34 per share, depending on the valuation methodology used. The current market price of $54.90 suggests that the stock may be significantly overvalued. This assessment is based on multiple valuation methods, including Discounted Cash Flow (DCF), Dividend Discount Model (DDM), and Earnings Power Value (EPV).

EQT's strong projected earnings growth, consistent cash flow generation, and conservative capital structure further support the notion that the stock may be overvalued. The company's historical dividend growth of 155.20% and a debt-to-equity ratio of 0.28 indicate a financially robust position. However, given the current market price, investors may need to consider the potential for long-term appreciation based on EQT's growth trajectory and financial strength.

Additionally, EQT's subsidiary, EQT Life Sciences, recently led an $80 million series A funding round for Swiss clinical-stage biotechnology company Mosanna Therapeutics. This investment highlights EQT's diversification strategy and its commitment to supporting innovative ventures in the life sciences sector.